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Obesity is a global pandemic leading to increased mortality and increased risk of 
cardiovascular disease. Bariatric surgery is an established treatment of obesity leading 
to weight loss and reduction of mortality. To further elucidate how bariatric surgery 
improves metabolic control, we explored the fatty acid (FA) profiles in morbidly 
obese subjects treated with lifestyle intervention and subsequent bariatric surgery.  
 
Methods. 
The intervention group consisted of 34 morbidly obese patients scheduled for bariatric 
surgery and the control group of 17 non-obese patients scheduled for elective 
laparoscopic procedures. The intervention group had to undergo lifestyle changes 
preoperatively. Fasting blood samples were drawn at admission, after lifestyle 
intervention and one year after bariatric surgery. 
 
Results. 
At admission, the morbidly obese patients had significantly higher levels of 
monounsaturated FAs (MUFAs) and lower levels of n-6 polyunsaturated FAs 
(PUFAs) and n-3 PUFAs than healthy controls (all p-values<0.05). In the intervention 
group, there was a significantly lower level of total FAs after lifestyle intervention, 
and from admission to one year after surgical intervention (both, p<0.05), primarily 
reflecting a lower proportion of saturated FAs (SFAs). Following bariatric surgery, 
but not after lifestyle changes, there was an increase in the proportion of n-3 PUFA 




Our findings suggest that a reduced proportion of the proposed anti-atherogenic n-3 
PUFAs characterizes morbidly obese individuals, and that this FA profile is reversed 
by bariatric surgery, but not by lifestyle intervention.  
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Obesity is a global pandemic leading to increased mortality and increased risk of 
cardiovascular disease [1-4]. Bariatric surgery is an established treatment of obesity 
causing weight loss, reversion of or better control of type 2 diabetes (T2D) and 
reduction of mortality [5-7]. Exactly how bariatric surgery mediates these effects is, 
however, not clear, and there are probably several mechanisms involved. 
 
Fatty acids (FAs) are mainly transported and stored as triglycerides in the human 
body and are important in cell metabolism and function involving their participation 
in various intracellular signalling pathways [8], and several studies have suggested 
their involvement in cardiovascular and metabolic related diseases. Elevated levels of 
total (non-esterified) free FAs are associated with increased risk for adverse events in 
coronary artery disease [9,10]. Saturated FAs (SFAs) like lauric acid (C12:0), 
myristic acid (C14:0) and palmitic acid (C16:0) increase low density lipoprotein 
(LDL) cholesterol, and trans-fatty acids, even if being unsaturated, also increase 
LDL-cholesterol. On the other hand, the polyunsaturated fatty acids (PUFAs) and 
especially the n-3 PUFAs including α-linolenic acid (ALA, C18:3), eicosapentaenoic 
acid (EPA, C20:5) and docosahexaenoic acid (DHA, C22:6) are thought to be 
protective of cardiovascular disease [11-13], although meta-analyses have not 
confirmed such a beneficiary effect so far [14,15]. n-6 PUFAs are precursors of potent 
inflammatory mediators such as certain prostaglandins and leukotrienes [16], but 
could also be the basis for certain resolving mediators like lipoxins [17], and the net 
effects of n-6 PUFAs are not clear.  
 
 
To further elucidate how bariatric surgery improves metabolic control we explored 
the FA profiles in morbidly obese subjects treated with lifestyle intervention and 
subsequent bariatric surgery.  
 
RESEARCH DESIGN AND METHODS 
Patients and controls 
The main study, including surgical techniques, has previously been described in detail 
[18], and the patients in the current substudy have recently been characterized [19]. 
Demographic data of the 51 participants are presented in Table 1.  
 
The study was performed in accordance with the Helsinki Declaration, approved by 
the regional ethics committee, and written informed consent was obtained of all 
participants.   
 
Life style intervention and diet 
The study design is described in Figure 1. Thirty-four morbidly obese patients 
(BMI 44.8±6.9 kg/m
2
, 17 diabetics and 17 non-diabetics) scheduled for bariatric 
surgery served as the intervention group. The control group consisted of 17 non-obese 
patients (BMI 25.3±2.1 kg/m
2
) scheduled for elective laparoscopic procedures. All 
patients in the intervention group had to undergo lifestyle changes resulting in a 
minimum of 10% weight loss before bariatric surgery. Patients who did not achieve 
10% preoperative weight loss were excluded from the study. In addition, the patients 
were free to contact the center for guidance if needed (according to Norwegian 
guidelines). 
The patients were encouraged to perform physical activity according to the 
Norwegian guidelines for treatment of morbidly obese patients [20]. The intervention 
group was informed to have a total of three main meals daily, and three to four small 
meals in between, and was advised to an energy restricted diet of 2000 kcal for males 
and 1500 kcal for women. This diet included a fat energy content of less than 30%, 
 
complex carbohydrates energy content of less than 50% and protein energy content up 
to 20%. Especially intake of saturated fats was discouraged, and the recommended 
proportion of total calories should be below 10% [21]. However, food intake and 
supplementation of different types of FAs including PUFAs were not registered. If the 
patients did not eat fatty fish products, they were advised to take n-3 PUFA 
supplementation. The average time for the patients to achieve 10% weight loss was 12 
weeks. During the 12 weeks of lifestyle intervention, the advises from dietists were 
repeated every two weeks. Furthermore, the patients were counselled before leaving 
hospital after surgery, as well as two times after surgery the following year before the 
next evaluation one year after surgery.  
 
Laboratory methods 
Fasting blood samples were collected with standard venipuncture and transported on 
ice and centrifuged at 2500g for 15 minutes at 4˚C, then stored in aliquots at -70˚C for 
later analysis in batch. Samples were drawn at admission (when entering the study), 
after lifestyle intervention (average of 12 weeks) and finally one year after bariatric 
surgery (Figure 1).      
 
Measurements of plasma total levels and composition of fatty acids 
Measurement of total level and composition of FAs was performed after extracting 
lipids from plasma using a mixture of chloroform and methanol (2:1) [22]. The 
extracts were transesterified using BF3 ⁄methanol [23]. Extracts of fatty acyl methyl 
esters (FAME) were heated in 0.5 mol L-1 KOH in ethanol⁄water solution (9:1), [24] 
to remove neutral sterols and nonsaponifiable material. Recovered FAs were re-
 
esterified using BF3 ⁄methanol. The methyl esters were quantified by gas 
chromatography as previously described [25]. 
The FAME were analyzed on a GC8000 Top GC (Carlo Erba Instrument, Italy), 
equipped with a flame ionization detector (FID), and a capillary column coated with a 
highly polar SP2340 phase (Supelco, USA) (60m x 0.25mm x 0.20m). Hydrogen 
constant flow 1.6ml/min was used as a carrier gas. PTV injector in split mode (split 
ratio 1:20) and FID were operated at 235°C. Column temperature was programmed 
from 130°C to 214°C (rate 1.4°C/min) and from 214°C to 220°C (rate 3.0°C/min). 
FAME were identified by comparison with known standards (Larodan Fine 
Chemicals, Sweden; Sigma, USA; Supelco, USA) and by GC/MS (GCQ Finnigan, 
USA) on the same column.  Quantification of the fatty acids was made with Chrom-
Card A/D 1.0 chromatography station (Carlo Erba Instruments, Italy) using 
heneicosanoic acid as the internal standard. Reference mixtures and individual FAME 
standards were used for calculation of response factors throughout the procedure. 
Standards of some minor fatty acids were not available on the market, and the 
response factors of these fatty acids were estimated according to the standards with 
the similar identity. The analytical reproducibility of whole procedure was regularly 
tested with intra assay coefficient of variation (CV) being below 1% for major fatty 
acids, about 2% for fatty acids proportion 0.1-1.0% of total fatty acids, and CV about 
3% for fatty acid proportion below 0.1% of total fatty acids. The EPA CV=1.3% and 
eicosatetraenoic acid (ETA, C20:4n-3) CV=2.2%. Similar precision CV values were 
measured in the plasma concentration range of individual fatty acids with the high 
linearity of the calibration curves (r>0.9999). 
 
Statistics                                                                                               
 
Numerical data are presented with mean and standard deviation (SD). An unpaired 
Student t-test was used to calculate the differences between the control group and the 
intervention group at admission. The D’Agostino-Pearson test was used to test for 
normality distribution. Non-parametric testing (Mann-Whitney) was performed if the 
samples were not normally distributed. A repeated measures one-way analysis of 
variance (RM one-way ANOVA) was used to calculate the longitudinally effect 
(admission/lifestyle intervention/one year postoperatively) of bariatric surgery on the 
different fatty acids. All tests were two-tailed and results with a p<0.05 were 
considered statistically significant. Correction for multiple testing was not performed 
due to the fact that the sample values were not independent. Analyses were done 
using PRISM 6 (Graph Pad Software Inc, La Jolla, CA). 
 
RESULTS 
Plasma FA profile in morbidly obese compared with controls (Table 2)                                                                                                             
There was no difference between the controls and the intervention group at admission 
regarding the total amount of FAs, and there were no differences in the proportion of 
saturated FAs (SFAs) and trans-FAs. Interestingly, however, the plasma levels of 
myristic acid (C14:0) and palmitic acid (C16:0) were significantly higher in the 
morbidly obese. The level of MUFAs was higher in the morbidly obese group 
compared to the control group, and this was mainly due to higher levels of palmitoleic 
acid (C16:1n-7) and oleic acid (C18:1n-9). In contrast, the proportion of both n-3 and 
n-6 PUFAs were significantly lower in the morbidly obese compared to controls. The 
lower proportion of n-3 PUFAs seems primarily to reflect lower levels of DPA and 
DHA. The lower level of n-6 PUFAs seems primarily to reflect a lower level of 
linoleic acid (C18:2n-6). Interestingly, the precursor for prostaglandins, arachidonic 
acid (AA, C20:4n-6) showed no differences between morbidly obese and controls. 
The results seem to be driven mainly by a difference between diabetics and controls 
as there were statistically significant differences between these groups. However, 
there was a similar, non-significant trend also for non-diabetic obese vs. controls. 
 
 
Plasma FA profiles during intervention in morbidly obese (Table 2) 
The fasting total FA concentration was lower after lifestyle intervention than at 
admission, and even lower one year after bariatric surgery. This difference seemed 
due to lower levels of mainly SFAs, and to some extent trans-FAs. The lower level of 
SFAs one year after bariatric surgery was mainly due to reduced level of palmitic acid 
 
(C16:0) and stearic acid (C18:0). Trans-FAs was lower after lifestyle intervention, 
driven by lower levels of trans vaccenic acid (C18:1t), while trans palmitoleic acid 
(C16:1n-7t) was unchanged. The reduction in C18:1t was not sustained one year after 
surgical intervention. The trans-FAs, however, had only 0.3 weighted % of the total 
FAs. For the reduction in total FAs, the same pattern with a significant decrease from 
admission to one year after surgery was seen in both diabetic (n=17) and non-diabetic 
(n=17) patients (data not shown). 
It was of interest to note that the total MUFA level increased from admission through 
the lifestyle intervention, but decreased on year after bariatric surgery compared to 
admission. This change in FA profile was primarily due to oleic acid (C18:1n-9) and 
vaccenic acid (C18:1n-7).  
Of note, whereas the proportion of n-3 PUFAs was unchanged from admission 
through the lifestyle intervention, there was a significant increase one year after 
bariatric surgery primarily reflecting an increase in DHA (C22:6n-3) and DPA 
(C22:5n-3). Moreover, while the proportion of eicosatetraenoic acid (ETA, C20:4n-3) 
and eicosapentaenoic acid (EPA, C20:5n-3) decreased during lifestyle intervention, it 
increased after bariatric surgery.  
The proportion of n-6 PUFAs was unchanged throughout the study period. Notably, 
however, whereas the proportion of AA (C20:4n-6) increased during lifestyle 
intervention, it returned to baseline levels one year after bariatric surgery.  
 
DISCUSSION 
In the present study, we show that morbidly obese individuals are characterized by 
higher levels of MUFAs as well as significantly lower proportions of both n-6 and n-3 
PUFAs compared to non-obese controls. Of note, following lifestyle intervention and 
bariatric surgery, there was a lower level of fasting total FAs, primarily reflecting a 
reduced level of SFAs. Furthermore, following bariatric surgery, but not after lifestyle 
intervention, there was an increase in the proportion of n-3 PUFA reaching levels 
comparable to healthy controls, primarily reflecting higher levels of DHA (C22:6n-3) 
and DPA (C22:5n-3). Our findings suggest that morbidly obese individuals are 
characterized by a decreased proportion of the proposed anti-atherogenic n-3 PUFAs, 
and that this disturbed FA profile is reversed by bariatric surgery, but not by lifestyle 
intervention. This increase in n-3 PUFA could potentially contribute to the beneficial 
effect of bariatric surgery on T2DM and mortality.  
  
Furthermore, in the present study we also found that the proportion of the n-3 PUFAs 
was significantly lower in the morbidly obese than in controls, reflecting lower levels 
of DHA and DPA. Moreover, whereas we observed unchanged levels of n-3 PUFAs 
from admission throughout lifestyle intervention, one year after bariatric surgery there 
was a significant higher proportion of n-3 PUFA, and again, primarily reflecting 
changes in DHA and DPA. Based on the suggested beneficial role of n-3 PUFA in 
cardiovascular and metabolic related disorders, these findings could be of particular 
interest in relation to the beneficial effects of bariatric surgery in morbidly obese 
individuals. Previously, Chalut-Carpentier et al noted that most of the n-3 PUFAs 
except DHA were significantly lower six months after bariatric surgery [26]. Herein 
we extend these findings by showing that these changes in n-3 PUFA were not 
 
obtained during dietary intervention, but were restricted to the period after bariatric 
surgery. The mechanisms for this effect are at present unclear, but could potentially 
reflect indirect or direct effects of loss of adipose tissue. It is unlikely that it was 
caused by changes in n-3 PUFA supplementation. Thus, the patients had close follow 
up by dietists in the lifestyle intervention period, and were advised to take n-3 
supplementation if they did not eat fatty fish, and importantly, lifestyle intervention 
did not induce any changes in the proportion of n-3 PUFA. In fact, the proportion of 
EPA and ETA decreased during lifestyle intervention whereas it increased after 
bariatric surgery. However, we cannot draw firm conclusions as to the mechanism for 
these changes since we lack accurate registration of intake through meals and 
supplementations during the study. Nevertheless, it appears that weight loss through 
lifestyle intervention (reduced intake) affects lipid metabolism differently from a 
weight loss achieved through bariatric surgery (reduced absorption). Whatever the 
mechanisms, the increase in the proportion of n-3 PUFA following bariatric could be 
of importance for the beneficial effect of this procedure on cardiovascular and related 
metabolic disorders.  
 
We demonstrate significantly lower levels of total FAs after lifestyle changes with a 
further decrease one year after bariatric surgery. The lower levels of total FAs were 
due to a reduction in the proportion of SFAs and to a lesser extent in trans-FAs. Our 
demonstration of a sustained reduction in SFAs can be important when keeping in 
mind the increasing awareness of the “gut-brain axis”, and the postulated effect that 
reducing saturated fats with bariatric surgery could affect hypothalamic neurons 
pivotal to human energy control [27]. Moreover, the reduction of SFAs one year after 
bariatric surgery was mainly due to reduced proportion of palmitic acid (C16:0) and 
 
stearic acid (C18:0). Importantly, palmitate, a term for the salts and esters of palmitic 
acid, has recently been shown to be an important inducer of inflammation in 
metabolic related disorders like diabetes and obesity through activation of NLRP3 
inflammasomes [28]. Previous studies have suggested an association between CRP 
and SFA in obese individuals [29,30], and we suggest that this could involve 
palmitate-NLRP3 inflammasome-related mechanisms. 
 
The level of n-6 PUFAs was lower in the morbidly obese compared to controls at 
admission. This finding has previously been observed in a meta-analysis [31]. The 
finding of lower levels of n-6 PUFAs in morbidly obese could be of clinical interest 
since the n-6 PUFAs have been considered pro-inflammatory [32], but no clear 
relationship with risk of cardiovascular disease has been demonstrated [33]. In the 
current study the levels of n-6 PUFAs remained unchanged, in contrast to the findings 
of Chalut-Carpentier et al who demonstrated a reduction in n-6 PUFAs 6 months after 
bariatric surgery [26]. Interestingly, however, we found that while AA, the 
prototypical inflammatory n-6 PUFA (C20:4n-6) [34], increased following dietary 
intervention, it returned to baseline level following bariatric surgery.  
 
In our study the proportion MUFAs was significantly higher in the morbidly obese 
than the controls, and the proportion of MUFAs was even higher after lifestyle 
intervention, though unchanged from baseline one year after bariatric surgery. Several 
national agencies recommend that the proportion of MUFAs is below 25 percent of 
the total energy intake, however, firm recommendations have not been made due to 
lack of evidence [35]. The increase in MUFA in our study was primarily due to an 
increased proportion of oleic acid (C18:1n-9) and vaccenic acid (C18:1n-7), and the 
 
mechanism for these changes are uncertain. We have previously shown that high 
levels of vaccenic acid is associated with disease severity and mortality in patients 
with heart failure, potentially reflecting harmful effects on the myocardium [36], and 
this MUFA has also been implicated in the pathogenesis of steatohepatitis [37]. At 
present, however, the role of vaccenic acid in obesity related disorders is unknown.  
 
Limitations 
The sample size in the current study was relatively small, and the findings need 
confirmation in larger study group. Diet registration and registration of FA 
supplementation (e.g. n-3 fatty acid intake) should be accounted for in later studies. 
Extended follow-up and repeated measurements in the control group should also be 
performed in later studies. 
 
Conclusion 
Morbidly obese individuals are characterized by higher levels of MUFAs as well as 
significantly lower proportion of both n-3 and n-6 PUFAs compared to non-obese 
controls. Following lifestyle changes and after bariatric surgery, there was a lower 
level of fasting total FAs, primarily reflecting a reduced level of SFAs. Furthermore, 
following bariatric surgery, but not after lifestyle changes, there was an increase in the 
proportion of n-3 PUFA reaching levels comparable to healthy controls. Our findings 
suggest that a reduced proportion of the proposed anti-atherogenic n-3 PUFAs 
characterizes morbidly obese individuals, and that this FA profile is reversed by 
bariatric surgery, but not by lifestyle intervention. This increase in n-3 PUFA could 
potentially contribute to the beneficial effect of bariatric surgery on T2DM and 
mortality. 
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Table 1. Baseline characteristics 
 
Controls (n=17) Intervention (n=34) 
Males 5 (29%) 15 (44%) 
Age (years) 48.1±14.9 43.2±9.0 
Type 2 Diabetes  1 (6%) 17 (50%) 
BMI (kg/m2) 25.3±2.1 44.8±6.9 
Cholesterol (mmol/l) 5.5±0.9 5.18±1.1 
Triglycerides (mmol/l) 1.1±0.3 1.8±0.9 
HbA1c (mmol/mol) 38± 2.0 49±13 














































Σ n-9 PUFAs 0.12±0.02
C20:3n-9 0.125±0.023








Values are mean±standard deviation, *p<0.05 controls compared to morbidly obese,§p<0.05, morbidly obese at admission compared to lifestyle.
#p<0.05 lifestyle intervention compared to 1 year after surgery,$p<0.05 admission compared to 1 year after surgery
FAs:Fatty Acids, Wt%:Weighted%, MUFAs:Mono Unsaturated FAs, PUFAs:Poly Unsaturated FAs
Morbidly obese, admission (n=34) Lifestyle intervention (n=34) 1 year after surgery (n=34)
3884±2457 3316±2304
§ 3053±1777$
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